Confirmation of biomarkers allows researchers to predict cardiovascular disease in patients with type 2 diabetes….
Researchers have done several studies in the search for biomarkers of incident CVD in patients with type 2 diabetes. At the European Association for the Study of Diabetes (EASD) 2013, researchers discussed data found from looking at five studies with a total of more than 2,300 type 2 diabetes patients. There were 42 biomarkers that were initially examined among these patients; however, only 16 of those biomarkers were examined further due to greater prediction of CVD. The following are the six most significant biomarkers that were found to be linked to CVD: N-terminal pro-B-type natriuretic peptide; apolipoprotein C-III; soluble RAGE; high-sensitivity troponin T; interleukin-6; and interleukin-15.
Of these six, interleukin-15 seems to be a novel link, as well as apolipoprotein C-III and soluble RAGE. These were unexpected and require further examination to predict incident CVD. Now that the researchers have narrowed in on these six particular biomarkers, replication studies are ongoing to further confirm their association with CVD in type 2 diabetes patients.
- Prediction of CVD in type 2 diabetes associated with six biomarkers
- Researchers examined more than 2,300 patients from several past studies to determine biomarkers that were present
- Total of 42 biomarkers were examined, then only 16 were examined further before narrowing down to six
European Association for the Study of Diabetes Annual Meeting, September 2013, Abstract #44